NCT02643667View on ClinicalTrials.gov

Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

April 12, 2023

Study Completion Date

April 12, 2023

Conditions

Prostate Cancer

Interventions

DRUG

Ibrutinib

-Ibrutinib will be supplied by Pharmacyclics Inc.

PROCEDURE

Radical prostatectomy

-Standard of care

Trial Locations (2)

63110

Washington University School of Medicine, St Louis

94158

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Pharmacyclics LLC.

All Listed Sponsors

collaborator

Pharmacyclics LLC.

INDUSTRY

lead

Washington University School of Medicine

OTHER